Jena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing of another similarly sized round. oncgnostics has developed the cervical cancer diagnostics test GynTect®, and a private investor circle now invests together with the current […]

2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering strategy. Early detection of cervical cancer is critical for patient’s health and survival. Current diagnostic methods are inefficient and fail to detect 50% of the […]

Lisbon/Jena, April 16th 2018 – Speculum S.A. is the exclusive licence partner of oncgnostics GmbH for the screening test GynTect® in Portugal. The test is designed to further specify abnormal results in screening examinations and to help determine the best treatment approach. In January, the biotech firm oncgnostics GmbH from Jena (Germany), concluded an […]

Jena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, GynTect®, for Slovakia and the Czech Republic. Following their successful crowd-funding via the platform Seedmatch, oncgnostics GmbH takes the next step for internationalization: the […]

https://www.oncgnostics.com/wp-content/uploads/2018/01/1801_Medirex_Bratislava_titel1.jpg7641574TowerPRhttps://www.oncgnostics.com/wp-content/uploads/2015/03/oncgnostics-logo1-300x138.pngTowerPR2018-01-31 14:37:442018-01-31 14:37:44Reliable test for cervical cancer triage now available in Slovakia and the Czech Republic: Biotech company oncgnostics concludes an exclusive partnership with the MEDIREX group

Jena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) for marketing GynTect® in China, Hongkong and Macao. The contract comprising four milestones rules the approval of GynTect® at the Chinese Food and Drug Agency […]

Jena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of cervical cancer – at the world-leading trade fair Medica. Between 14th and 17th of November 2016 the epigenetics experts will explain the advantages of the […]

Jena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The test has been revised now, offering an extension of its application, as compared to the first version. This extended version of GynTect is now available […]

Bangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics. GynTect is a molecular test, which allows timely clarification, if a patient with abnormal Pap test finding and/or a positive test for the cancer-causing human papillomaviruses […]

Jena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces the GynTect® test, prior to Medica 2015. […]

oncgnostics GmbH

The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.

oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.